Scarica l'app Stockscreener
74.30
0.18%
0.13
Dopo l'orario di chiusura:
74.30
Precedente Chiudi:
$74.17
Aprire:
$74.5
Volume 24 ore:
2.40M
Relative Volume:
0.97
Capitalizzazione di mercato:
$11.84B
Reddito:
$705.14M
Utile/perdita netta:
$-453.90M
Rapporto P/E:
-24.44
EPS:
-3.04
Flusso di cassa netto:
$-551.29M
1 W Prestazione:
+4.85%
1M Prestazione:
+13.57%
6M Prestazione:
+141.94%
1 anno Prestazione:
+93.54%
Intervallo 1D:
$74.02
$75.49
Intervallo di 1 settimana:
$71.14
$75.49
Portata 52W:
$23.95
$75.49
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
74.30 | 12.01B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Volatility clustering patterns for Ionis Pharmaceuticals Inc.July 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
Will Ionis Pharmaceuticals Inc. (ISI) stock profit from AI boomInsider Buying & High Conviction Investment Ideas - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionMarket Performance Report & AI Based Trade Execution Alerts - newser.com
Is Ionis Pharmaceuticals Inc. stock poised for growthEarnings Overview Report & Growth Focused Entry Point Reports - newser.com
Wall Street Zen Downgrades Ionis Pharmaceuticals (NASDAQ:IONS) to Hold - MarketBeat
Can Ionis Pharmaceuticals Inc. stock hit analyst price targetsWeekly Gains Summary & Technical Analysis for Trade Confirmation - newser.com
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91 - simplywall.st
US$81.91That's What Analysts Think Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Is Worth After These Results - Yahoo Finance
Pinnacle Associates Ltd. Sells 113,978 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Can Ionis Pharmaceuticals Inc. stock resist market sell offsWeekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Candlestick signals on Ionis Pharmaceuticals Inc. stock today2025 Top Gainers & Risk Controlled Daily Trade Plans - newser.com
Published on: 2025-10-31 22:00:20 - newser.com
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $99.00 - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year High on Earnings Beat - MarketBeat
Royal Bank Of Canada Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Given Strong-Buy Rating at Raymond James Financial - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $90.00 at Needham & Company LLC - MarketBeat
Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Will Ionis Pharmaceuticals Inc. stock deliver better than expected guidance2025 Growth vs Value & AI Enhanced Trading Signals - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosTrade Analysis Report & Expert Approved Momentum Ideas - newser.com
Is Ionis Pharmaceuticals Inc. stock ready for breakoutJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
IQ EQ FUND MANAGEMENT IRELAND Ltd Increases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
What is the fair value estimate for Ionis Pharmaceuticals Inc. (ISI) stock in 2025Quarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
Why Ionis Pharmaceuticals Inc. stock remains on watchlistsJuly 2025 Snapshot & Daily Profit Maximizing Tips - newser.com
Ionis Pharmaceuticals Faces Investor Risks Amid Market Volatility and Milestone Uncertainties - TipRanks
Ionis Pharmaceuticals stock hits 52-week high at $74.42 By Investing.com - Investing.com Philippines
Decoding Ionis Pharmaceuticals Inc (IONS): A Strategic SWOT Insi - GuruFocus
Published on: 2025-10-30 23:08:16 - newser.com
Ionis Pharmaceuticals, Inc. (IONS) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
TD Cowen Raises Ionis Pharmaceuticals (IONS) Price Target to $99 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Morgan Stanley Raises Price Target for Ionis Pharmaceuticals (IO - GuruFocus
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook - sharewise.com
Ionis Pharmaceuticals Inc (IONS) Q3 2025 Earnings Call Highlight - GuruFocus
Barclays Raises Ionis Pharmaceuticals (IONS) Price Target to $95 - GuruFocus
HC Wainwright Maintains 'Buy' Rating on Ionis Pharmaceuticals (I - GuruFocus
RBC Capital Maintains Outperform Rating on IONS, Raises Price Ta - GuruFocus
Ionis Pharmaceuticals (IONS) Receives Rating Reiteration and Pri - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Posts Quarterly Earnings Results, Beats Estimates By $0.35 EPS - MarketBeat
Ionis (IONS) Q3 2025 Earnings Call Transcript - AOL.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2025 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals: Strong Q3 Performance and Promising Future Catalysts Support Buy Rating - TipRanks
Ionis Pharmaceuticals Inc. stock trend outlook and recovery pathWeekly Stock Summary & Weekly Market Pulse Alerts - newser.com
Needham Raises Price Target for Ionis Pharmaceuticals (IONS) to $90 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals’ ION464 Study: A Potential Breakthrough for Multiple System Atrophy - MSN
Is Ionis Pharmaceuticals Inc. stock in correction or buying zone2025 Year in Review & Proven Capital Preservation Tips - newser.com
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):